While earlier reports suggested that risk of subsequent ipsilateral IBC is decreased in women with ER+ and PR+ lesions and increased in those with HER2+ lesions [7, 9], more recent summary estimates of risk presented in meta-analyses suggested no statistically significant alteration in risk in association these markers [8, 10]. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.